Last updated October 21, 2026. Approval line checked October 21, 2026. No compounding source date is assigned.
FDA status
Approved
Approved. Teduglutide is the active ingredient in Gattex, FDA-approved for short bowel syndrome. It is a GLP-2 analog, not an approved weight-management GLP-1. Approval is specific to the product and indication.
Drugs@FDA: Gattex (NDA 203441)By signing up you agree to get PeptideX update emails. Unsubscribe anytime. Educational only, not medical advice.
Evidence tier
Human RCT. The tier is the highest indexed study type. It is not a safety rating and it is not an FDA approval. Confidence score 5/5. 366 PubMed citations indexed.
Products sold as "research use only" are not approved for human use. FDA warning.
Teduglutide (Gattex/Revestive) is a recombinant GLP-2 analog with a single amino acid substitution (Ala→Gly at position 2) conferring DPP-4 resistance, extending its half-life from 7 minutes (native G
What the literature studies
GLP-1 Research
Evidence tier
Human RCT
Compounding record
Status not verified
Status not verified. No product-specific FDA primary source is recorded for this entry. FDA approval and compounding eligibility are not verified. Research information is not evidence of FDA approval. Approval, where applicable, is specific to a drug product, indication and route. Research information is not evidence of FDA approval. Approval, where applicable, is specific to a drug product, indication and route.
Regulatory source not verified; no checked date is assigned.
Teduglutide's intestinotrophic mechanism may accelerate growth of pre-existing colorectal polyps; colonoscopy within 6 months prior to initiation and every 5 years during treatment
By signing up you agree to get PeptideX update emails. Unsubscribe anytime. Educational only, not medical advice.
Educational only. Not medical advice. This page does not give doses or sourcing. See the medical and editorial disclaimer.